Q-Line Biotech shareholders and shareholding pattern
NSE: QLINEHealthcare Equipment & Supplies
Q-Line Biotech Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2026 · Issue price ₹343
Last close ₹544.45down ₹4.60 (0.84%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹549.05.
28 Oct: open ₹551.00, high ₹567.95, low ₹530.65
Range of traded prices from listing on 29 May 2026 to 28 Oct 2026
₹431.00Low, 29 May 2026₹735.00High, 15 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹1,270 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.79
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 22.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.92
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 42,80067.3% delivered
Q-Line Biotech's shareholding pattern for Sep 2026, filed on 20 Oct 2026: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Q-Line Biotech, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters67.51%
- Foreign institutions0.88%
- Indian institutions8.15%
- Individuals and others23.45%
| Per cent | Sep 2026 |
|---|---|
| 67.51% | |
| Indian promoters | 67.51% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 32.49% |
| Shares in issue | 2,33,28,199 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 1,70,74,999 |
| Promoters' shares locked in | 1,57,50,000 |
A dash is a line the filing did not state.
Q-Line Biotech promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is SAURABH GARG, 43.69%. The filing names 16 more members with no shares.
| Holder | |||
|---|---|---|---|
| SAURABH GARGIndividuals and Hindu undivided families | 43.69% | 1,01,91,000 | 100.00% |
| AMITA GARGIndividuals and Hindu undivided families | 16.88% | 39,37,480 | 100.00% |
| ABHAY AGRAWALIndividuals and Hindu undivided families | 3.24% | 7,56,010 | 100.00% |
| AJAY KUMAR MAHANTYIndividuals and Hindu undivided families | 3.21% | 7,50,000 | 100.00% |
| AMIT AGARWALIndividuals and Hindu undivided families | 0.14% | 31,510 | 100.00% |
| SHUBHAM GARGIndividuals and Hindu undivided families | 0.14% | 31,500 | 100.00% |
| AYUSH GARGIndividuals and Hindu undivided families | 0.14% | 31,500 | 100.00% |
| PUSHPLATA GARGIndividuals and Hindu undivided families | 0.09% | 21,000 | 100.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Q-Line Biotech, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2026 |
|---|---|
| CARNELIAN AIF CATEGORY I TRUST-SCHEME 1Alternative investment funds | 1.44% |
| ABAKKUS FLEXI EDGE FUND-1Alternative investment funds | 1.05% |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the May 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Indian institutions: CARNELIAN AIF CATEGORY I TRUST-SCHEME 1 1.44%, +0.23 pts
- Individuals and others: Vikas Vijaykumar Khemani no longer named, from 1.87%; HEM FINLEASE PRIVATE LIMITED .-PROP no longer named, from 1.34%; CALLIOPE CAPITAL ADVISORS LLP no longer named, from 1.00%